The non-animal alternatives testing market entails of sales of non-animal alternatives testing products and services that do not contain the practice of animals for tests to determine the protection standards for products. The non-animal alternatives testing market includes testing for drugs, cosmetic products using non- animal testing procedures. Organs-on-chip, In-vitro test, In-silico test are some examples of methods and methodologies used as an alternate to animal testing.
According to the report analysis, ‘Non-Animal Alternatives Testing Market Global Report 2020-30’ states that the global non-animal alternatives testing market was worth USD 1.11 billion throughout 2019. It is predicted to augment at a compound annual growth rate (CAGR) of 11.62% and reach USD 1.65 billion by 2023. The corporates in the non-animal testing market are progressively more investing in technologies such as organs on the chip technology as an alternate to animal testing. Organs- on the- chip method encompasses human cells on a chip which mimics the structure and function of human organs and organs system instead of utilizing of animal for the test.
Following the trend, during 2018, Emulate was financed an amount of USD 36 million from its founder’s fund and ALS Investment Fund, SciFi VC, Glass Wall Syndicate Association to prolonged its biological capabilities to Liver-Chip, Intestine-Chip, Lung-Chip, and Brain-Chip, and to its human-relevant replicas of thrombosis and immune system modulation. Moreover, the ALS Investment Fund, SciFi VC and Glass Wall Syndicate Association are venture capital and private equity firm that backings and finances biotech corporates.
In addition, during 2018, Thermo Fisher Scientific Inc., a USA based life sciences research company, obtained Advanced Bioprocessing business from Becton, Dickinson and Company for USD 477 million in cash. Through this acquisition Thermo Fisher Scientific Inc. focused to enlarge its bioproduction portfolio by utilizing the cell-culture media products of the Becton, Dickinson and Company. The Becton, Dickinson and Company is a USA reliant medical device company.
However, according to Cruelty Free International, during 2018, around the UK almost 40 eye irritation tests, 10,275 acute lethal toxicity tests, and 638 pyrogenicity experiments were accompanied on live rabbits. Cruelty Free International is an U.K based animal security and advocacy group. The legal requirements in some countries for necessary animal testing will limit the growth of the market.
Whereas, the assistance from the government and non-governmental organizations booms the growth of the non-animal testing market. The government organizations implements laws and regulations, promotions funds to support the non-animal testing approaches such as tests on human volunteers, advanced computer-modelling techniques and also funds studies with the human volunteer. In order to assistance the non-animal testing, US Environmental Protection Agency (EPA), during 2019, awarded USD 4.25 million to the USA based universities involving Johns Hopkins University, Vanderbilt University, Oregon State University, and the University of California to research for substitute tests replacing animals with non-animal alternatives and to generate the test procedures less hurting to the laboratory animals. Similar research programs to encourage non-animal testing measures are also initiated by regions such as Denmark, Brazil, Germany, Switzerland, Australia, China and Korea. The constant assistance from the government propels the growth of the non-animal testing market. Therefore, in the near years, it is predicted that the market of non-animal alternatives testing will increase around the globe more significantly.
For More Information, Click on the Link Below:-
Ankur Gupta, Head Marketing & Communications